Skip Navigation

Business

Allergan announces US$350m investment in Westport site; will create 200 new jobs over four years

Tags: IDA Ireland,
Allergan announces US$350m investment in Westport site; will create 200 new jobs over four years

Allergan announces US$350m investment in Westport site; will create 200 new jobs over four years

Allergan Pharmaceuticals Ireland is investing US$350m in its Westport site to expand its development and manufacturing capacity, the company announced today.

The expansion will result in the creation of around 200 new jobs at the Westport site over the next four years and an estimated 250 indirect jobs locally during the construction period. The company currently employs more than 900 people in Ireland, mainly in manufacturing and development as well as financial services and customer support.

The investment will primarily enable company to expand the manufacturing capability for Botox and to develop a manufacturing base for the next generation of biologic products currently in the Allergan pipeline.

It will also support expansion of manufacturing and development activities across the other franchises within the Allergan portfolio.

Pat O’Donnell, managing director, Allergan Pharmaceuticals Ireland, said the investment underscores the strategic importance of the Westport site within the Allergan manufacturing network.

“Based on Allergan’s present strategic plans, we anticipate that demand for Botox will continue to grow, fuelled by recent approvals of the product for the treatment of neurogenic detrusor overactivity and the treatment of chronic migraine in many countries around the world,” he said.

“The Allergan board has approved the acquisition of the technology park located next to the Allergan site, giving us the space for this expansion. I would like to recognise the work of the IDA and local agencies for having the vision to develop the technology park and for agreeing to our acquisition of these facilities, which will allow us to meet our current and future growth plans.”

Allergan is expecting detailed design and planning work to start early this year.

IDA Ireland CEO, Barry O’Leary, welcomed the announcement and noted that Allergan already contributes significantly to the national and local economies, investing an average of US$25m capital expenditure per annum in Ireland in recent years.

“In addition to excellence in manufacturing and consistent with IDA strategy, the Westport site has increased its involvement in the late stage development of new products,” he said. “This announcement is a welcome endorsement of Ireland’s record with the development and manufacturing model and represents a further boost for the vibrant pharma chemical sector here.”

Tags: IDA Ireland,